Building Modunai

Key milestones on our journey to develop next-generation cancer immunotherapies

NEWS & UPDATES

AUG 2026: In vivo proof-of-concept — MOD2 demonstrates antitumor activity in an aggressive, immune-cold syngeneic TNBC model.

SEP 2026: NIH SBIR application submitted — Application submitted to advance MOD2 preclinical development.

MAY 2026: Academic collaboration — Preclinical collaboration established with investigators at BIDMC / Harvard Medical School.

APR 2026: Platform IP filed — First provisional patent application filed covering Modunai’s tumor-directed immunotherapy platform.

APR 2026: Big Tree portfolio — Modunai joins the Big Tree portfolio following its Private Investor Showcase.

OCT 2025: In vitro proof-of-concept — Early studies establish biological proof of concept for the TABI™ platform.

SEP 2025: Mansfield Bio-Incubator — Modunai joins the Mansfield Bio-Incubator, expanding our presence within the Massachusetts biotech ecosystem.

JUL 2025: UMass Amherst — Modunai joins the UMass Amherst Core Facilities program to accelerate discovery.